LOVELIVE GRAPHICS Ltd

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of themore

Developer of a data warehousing and streaming technology intended to operationalize data into real-time streams. The company focuses on offering a single platform for effectively warehousing data and performing analytics instantaneously without the need for duplication and ELT and utilizes indexing, statistics, and other techniques to optimize nonsequential access to data, challenging the accepted practice of separate data, enabling data scientists, engineers and analysts to harness event streaming data so that they can overcome challenges and thrive in a data-centric world.

Developer of online applications intended for e-commerce merchants. The company provides a toolkit that delivers a comprehensive suite of ecosystem-leading applications, thereby enabling clients to run their businesses in an enhanced manner, grow faster and deliver experiences to their customers.